Acambis of the UK has been awarded two grants under the US Department ofDefense's Dual Use Science & Technology program, to the tune of $1.3 million, to support its efforts in developing vaccines to prevent diarrhea caused by enterotoxigenic Escherichia coli and Campylobacter.
Acambis' ETEC vaccine is an orally-administered mixture of five live, attenuated strains, the first of which has already been tested in Phase I trials. The Campylobacter program has just entered preclinical development and is based on a bacterial antigen delivered via Acambis' proprietary live, attenuated Salmonella typhi vector (HolaVax) technology. Orally-active clinical candidates from the latter program are scheduled to enter trials in 2003.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze